BioLogic Summit 2025
Conference dates: January 13-16, 2025
Booth: 113
Location: San Diego, CA
Poster sessions
Poster 1 Title: Full Antigen Kinetics of Fabs Directly from Crude Periplasmic Extracts on an Anti-CH1 Capture Surface
Presenter: Chris Silva, Carterra
Abstract: Characterizing detailed binding kinetics of antibody fragments directly from bacterial periplasmic extracts (PPEs) has been historically challenging because purification of all primary hits is time and resource intensive. Here we have described a highly scalable, yet data rich approach to characterizing the binding kinetics of Fab candidates directly from crude PPE sources. The throughput of the LSAXT can measure full kinetics (ka, kd, and KD) for thousands of Fabs in a single week, while eliminating the need for purification. The assay demonstrated here using 96 unique Fabs required fewer than 9 ug of antigen and was completed in 10 hrs. Importantly, this set of 96 clones is only one-twelfth of the 1152 clone capacity that can be analyzed in a single experiment. The ability to quantitate complete kinetic profiles for responses with Rmax values as low as 5 RU emphasizes that data can be obtained even for poorly expressing clones and is a key benefit of the enhanced sensitivity of the LSAXT.
Poster 2 Title: Accelerating the Discovery of Therapeutic Antibodies Using High Throughput SPR
Presenter:Chris Silva, Carterra
Abstract: Throughput, speed, resolution, and sample consumption are typically key limiting- factors for detailed kinetic characterization early in antibody discovery campaigns. Here, we show that high throughput surface plasmon resonance (SPR) can be used to rapidly generate high quality kinetic data from 384 antibodies in parallel with minimal sample consumption. Additionally, epitope binning assays can be performed routinely on up to 384 antibodies per array, providing unprecedented throughput that allows for early assessment of your library’s epitope coverage with exquisite epitope discrimination, facilitating the identification of clones targeting unique epitopes. The ability to characterize binding kinetics, affinity, and epitope specificity on large antibody panels with minimal sample consumption at early stage research is highly advantageous in drug discovery because it helps to accelerate library-to-lead triage.